Probable 4-Repeat Tauopathy Criteria Predict Brain Amyloid Negativity, Distinct Clinical Features, and FDG-PET/MRI Neurodegeneneration Patterns in Corticobasal Syndrome

Overview

Journal Mov Disord Clin Pract

Publisher Wiley

Specialty Neurology

Date 2023 Dec 29

PMID 38155526

Authors

Jacy Bezerra Parmera

Camila de Godoi Carneiro

Isabel Junqueira de Almeida

Marcos Castello Barbosa de Oliveira

Pedro Melo Barbosa

Adalberto Studart-Neto

Carla Rachel Ono

Ricardo Nitrini

Carlos Alberto Buchpiguel

Egberto Reis Barbosa

Sonia Maria Dozzi Brucki

Artur Martins Coutinho

Affiliations

Soon will be listed here.

Abstract

Background: Corticobasal syndrome (CBS) is associated with diverse underlying pathologies, including the four-repeat (4R)-tauopathies. The Movement Disorders Society (MDS) criteria for progressive supranuclear palsy (PSP) proposed the novel category "probable 4R-tauopathy" to address the phenotypic overlap between PSP and corticobasal degeneration (CBD).

Objectives: To investigate the clinical ability of the MDS-PSP criteria for probable 4R-tauopathy in predicting a negative amyloid-PET in CBS. Additionally, this study aims to explore CBS patients classified as 4R-tauopathy concerning their clinical features and neuroimaging degeneration patterns.

Methods: Thirty-two patients with probable CBS were prospectively evaluated and split into those who fulfilled or did not fulfill the 4R-tauopathy criteria (CBS-4RT+ vs. CBS-4RT-). All patients underwent positron emission tomographies (PET) with [ F]fluorodeoxyglucose and [ C]Pittsburgh Compound-B (PIB) on a hybrid PET-MRI scanner to perform multimodal quantitative comparisons with a control group.

Results: Eleven patients were clinically classified as CBS-4RT+, and only one had a positive PIB-PET. The CBS-4RT+ classification had 92% specificity, 52% sensitivity, and 69% accuracy in predicting a negative PIB-PET. The CBS-4RT+ group presented with dysarthria and perseveration more often than the CBS-4RT- group. Moreover, the CBS-4RT+ group showed a prominent frontal hypometabolism extending to the supplementary motor area and striatum, and brain atrophy at the anterior cingulate and bilateral striata.

Conclusions: The 4R-tauopathy criteria were highly specific in predicting a negative amyloid-PET in CBS. Patients classified as 4R-tauopathy presented distinct clinical aspects, as well as brain metabolism and atrophy patterns previously associated with tauopathies.

Citing Articles

The Spectrum of Cognitive Impairment in Atypical Parkinsonism Syndromes: A Comprehensive Review of Current Understanding and Research.

Jellinger K Diseases. 2025; 13(2).

PMID: 39997046 PMC: 11854393. DOI: 10.3390/diseases13020039.

Pathomechanisms of neuropsychiatric disturbances in atypical parkinsonian disorders: a current view.

Jellinger K J Neural Transm (Vienna). 2025; 132(4):495-518.

PMID: 39954076 DOI: 10.1007/s00702-025-02890-7.

References

Hughes C, Berg L, Danziger W, COBEN L, Martin R . A new clinical scale for the staging of dementia. Br J Psychiatry. 1982; 140:566-72. DOI: 10.1192/bjp.140.6.566. View

Nitrini R . Elementary motor perseveration in early diagnosis of progressive supranuclear palsy. Arq Neuropsiquiatr. 1987; 45(1):29-32. DOI: 10.1590/s0004-282x1987000100004. View

Boeve B, Lang A, Litvan I . Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol. 2003; 54 Suppl 5:S15-9. DOI: 10.1002/ana.10570. View

Rittman T, Ghosh B, McColgan P, Breen D, Evans J, Williams-Gray C . The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry. 2013; 84(5):544-51. PMC: 3623037. DOI: 10.1136/jnnp-2012-303618. View

Coutinho A, Busatto G, de Gobbi Porto F, Faria D, Ono C, Garcez A . Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters. Eur J Nucl Med Mol Imaging. 2020; 47(11):2666-2680. DOI: 10.1007/s00259-020-04714-0. View

Jabbari E, Holland N, Chelban V, Jones P, Lamb R, Rawlinson C . Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurol. 2019; 77(3):377-387. PMC: 6990759. DOI: 10.1001/jamaneurol.2019.4347. View

Grimm M, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E . How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord. 2019; 34(8):1228-1232. PMC: 6699888. DOI: 10.1002/mds.27666. View

Yamane T, Ishii K, Sakata M, Ikari Y, Nishio T, Ishii K . Inter-rater variability of visual interpretation and comparison with quantitative evaluation of C-PiB PET amyloid images of the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging. 2016; 44(5):850-857. DOI: 10.1007/s00259-016-3591-2. View

Ling H, OSullivan S, Holton J, Revesz T, Massey L, Williams D . Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010; 133(Pt 7):2045-57. DOI: 10.1093/brain/awq123. View

10.

Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

11.

Koga S, Josephs K, Aiba I, Yoshida M, Dickson D . Neuropathology and emerging biomarkers in corticobasal syndrome. J Neurol Neurosurg Psychiatry. 2022; . PMC: 9380481. DOI: 10.1136/jnnp-2021-328586. View

12.

Burrell J, Hodges J, Rowe J . Cognition in corticobasal syndrome and progressive supranuclear palsy: a review. Mov Disord. 2014; 29(5):684-93. DOI: 10.1002/mds.25872. View

13.

Ouchi H, Toyoshima Y, Tada M, Oyake M, Aida I, Tomita I . Pathology and sensitivity of current clinical criteria in corticobasal syndrome. Mov Disord. 2013; 29(2):238-44. DOI: 10.1002/mds.25746. View

14.

Pfeffer R, Kurosaki T, Harrah Jr C, Chance J, Filos S . Measurement of functional activities in older adults in the community. J Gerontol. 1982; 37(3):323-9. DOI: 10.1093/geronj/37.3.323. View

15.

Whitwell J, Tosakulwong N, Botha H, Ali F, Clark H, Duffy J . Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. Neuroimage Clin. 2020; 25:102152. PMC: 6961761. DOI: 10.1016/j.nicl.2019.102152. View

16.

Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M . Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol. 2020; 77(11):1408-1419. PMC: 7341407. DOI: 10.1001/jamaneurol.2020.2526. View

17.

Boxer A, Qureshi I, Ahlijanian M, Grundman M, Golbe L, Litvan I . Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019; 18(6):549-558. DOI: 10.1016/S1474-4422(19)30139-5. View

18.

Peterson K, Patterson K, Rowe J . Language impairment in progressive supranuclear palsy and corticobasal syndrome. J Neurol. 2019; 268(3):796-809. PMC: 7914167. DOI: 10.1007/s00415-019-09463-1. View

19.

Lee S, Rabinovici G, Mayo M, Wilson S, Seeley W, DeArmond S . Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011; 70(2):327-40. PMC: 3154081. DOI: 10.1002/ana.22424. View

20.

Hoglinger G . Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No. Mov Disord Clin Pract. 2018; 5(2):141-144. PMC: 6174469. DOI: 10.1002/mdc3.12582. View